Alpha Cognition (ACOG) vs NervGen Pharma (NGEN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Alpha Cognition (ACOG) has outperformed NervGen Pharma (NGEN) over the past year, gaining 17.1% versus a loss of 48.2%. Alpha Cognition is the larger company by market cap ($196.9 million vs $188.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ACOG | NGEN |
|---|---|---|
| Share price | $9.04 | $1.75 |
| Market cap | $196.87M | $188.16M |
| 1-day change | 0.00% | +0.57% |
| YTD return | +39.08% | -68.75% |
| 1-year return | +17.10% | -48.18% |
| 5-year return | — | -7.41% |
| EPS (TTM) | $-1.32 | $-0.57 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $10.14 | $6.30 |
| 52-week low | $4.50 | $1.58 |
| Distance from 52-week high | -10.85% | -72.22% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +99.12% | +471.43% |
| Average volume | 125.72K | 565.19K |
| Shares outstanding | 21.78M | 107.52M |
| Employees | 71 | 9 |
| Sector | Healthcare | Health Care |
| Industry | Biotechnology | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ACOG has outperformed NGEN by 65.3 percentage points over the past year.
- The two companies sit in different sectors: Alpha Cognition in Healthcare and NervGen Pharma in Health Care.
About Alpha Cognition
ACOG stock →Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company's commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer's disease.
Healthcare · Biotechnology · 71 employees
About NervGen Pharma
NGEN stock →NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company's lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer's disease; and NVG-300, which is in a preclinical model of ischemic stroke, amyotrophic lateral sclerosis, and confirmatory SCI study.
Health Care · Biotechnology: Pharmaceutical Preparations · 9 employees
ACOG vs NGEN FAQ
Which is bigger, Alpha Cognition or NervGen Pharma?
Alpha Cognition (ACOG) is larger, with a market capitalization of $196.87M compared with $188.16M for NervGen Pharma (NGEN).
Which stock has performed better over the past year, ACOG or NGEN?
ACOG returned +17.10% over the past 12 months, compared with -48.18% for NGEN (price return, excluding dividends). Past performance does not predict future results.
Are Alpha Cognition and NervGen Pharma in the same industry?
No. Alpha Cognition is in the Healthcare sector, while NervGen Pharma is in Health Care.